SABCS国际视野丨Matteo Lambertini教授：BRCA突变乳腺癌患者治疗策略优化及SABCS大会亮点解读

肿瘤瞭望：请您首先简单介绍一下自己，以及您的研究领域和研究方向。

肿瘤瞭望：您能简要介绍一下您在本次会议上展示的研究内容吗？

At the San Antonio Breast Cancer Symposium 2024, we have presented the results of a large international core study that included more than 5,200 patients with diagnosis of breast cancer at a young age, so 40 years or less. And all of them were known to carry a germline BRCA pathogenic variant in the BRCA genes. So they were young BRCA carriers with diagnosis of breast cancer. And in this specific analysis, we focused on the role of risk-reducing surgeries, and specifically we looked into the association between risk-reducing surgeries and survival outcomes. And the main results of this analysis have been that both risk-reducing mastectomy as well as risk-reducing salpingophorectomy were associated with significant improvement in overall survival（OS）, disease-free survival（DFS）, and breast cancer-free interval（BCFI）, with a major advantage that was observed in all the patient subgroups. But these are data, again, that should be considered for a special patient population, so those women that are BRCA carriers and have been already diagnosed with breast cancer at a young age.

肿瘤瞭望：在您的专业领域内，本次会议中有哪些值得关注的突破性研究和重要进展？

At the San Antonio Breast Cancer Symposium, we have had a lot of important trials presented in the breast cancer field. During the first day general session, we had a publication in the New England Journal of Medicine of the results of the EMBER-3 trial investigated an oral SERD called Imlunestrant in the management of patients with Hormone receptor-positive , HER2 negative, advanced breast cancer with endocrine-resistant disease. And in this trial, the authors have investigated the benefit of this SERD single-agent or in combination with abemaciclib as compared to standard single-agent endocrine therapy, so fulvestrant or aromatase inhibitors. This ended in The New England publication, so very important data that can be practice-changing.

But this conference is also very much appreciated because it's a very multidisciplinary event in which we have news not only in the medical oncology field, but also in other fields, including surgery, including radiotherapy, as well as survivorship. So many, many news to be followed at the San Antonio Breast Cancer Symposium.

肿瘤瞭望：在本次会议中，您有没有获得一些有价值的见解可以与我们的观众分享？这些见解将如何影响您的临床实践或未来的研究方向？

Yeah, based on the data presented at the San Antonio Breast Cancer Symposium, we say that the critical word is optimization, treatment optimization. So trying to improve the way we care about our patients with breast cancer in terms of trying to reduce the burden of treatment when not so much treatment is needed. And on the other side, to escalate the treatments to doing something more for those women that require more treatment. There has been a lot of presentation at the conference on studies in these two directions. So escalation or de-escalation of local treatment as well as systemic therapies that will definitely help us improve in the way we care about our patients with breast cancer and so to optimize the treatment of our patients.